What is CNTX's current stock price?

CNTX (Context Therapeutics Inc.) is currently trading at $2.56 with a market cap of $234.9M.

What sector is Context Therapeutics Inc. in?

Context Therapeutics Inc. (CNTX) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is CNTX a good stock to buy?

Analysts have a Buy consensus on CNTX with a price target of $5.25. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

CNTX Context Therapeutics Inc.

Healthcare

$2.56+0.00%OpenMarket Cap: $234.9M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

4.74

P/S

0.00

EV/EBITDA

-4.34

DCF Value

$0.67

FCF Yield

-13.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-60.0%

ROA

-68.3%

ROIC

-82.9%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-8.7M	$—
Q4 null	$0.00	$-13.0M	$—
FY null	$0.00	$-36.1M	$—
Q3 null	$0.00	$-9.7M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$5.25

Target (Median)

$5.25

Target Range

$4.50 - $6.00

3 Strong Buy7 Buy0 Hold0 Sell0 Strong Sell

GuggenheimBuy

2026-03-24

Piper SandlerOverweight

2026-03-24

D. Boral CapitalBuy

2026-03-24

HC Wainwright & Co.Buy

2025-11-06

D. Boral CapitalBuy

2025-11-06

Trading Activity

Insider Trades

View All

Minai-Azary Jennifer Lynnofficer: Chief Financial Officer

SellMon Feb 23

Levit Alex C.officer: Chief Legal Officer, Corp. Sec

SellMon Feb 23

Lehr Martin A.director, officer: Chief Executive Officer

SellMon Feb 23

Chagin Karen Deborahofficer: Chief Medical Officer

SellMon Feb 23

West Lindadirector

SellThu Jun 12

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.57

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Peers

IMA